High-density lipoprotein, but not low-density lipoprotein cholesterol levels influence short-term prognosis after...

Area of Science:

• Cardiovascular Medicine
• Clinical Lipidology
• Pharmacology

Background:

• Patients with acute coronary syndrome (ACS) experienced reduced cardiovascular events with atorvastatin treatment in the MIRACL study.
• Understanding the predictive role of plasma lipoproteins in ACS is crucial for risk stratification and treatment optimization.

Purpose of the Study:

• To determine if baseline and 6-week plasma lipoprotein levels predict clinical outcomes in ACS patients treated with atorvastatin.
• To investigate the relationship between lipid profiles and cardiovascular event risk following ACS.

Main Methods:

• Utilized Cox proportional hazards models to analyze the association between lipoproteins and clinical endpoints.
• Assessed baseline and 6-week levels of LDL-C and HDL-C in ACS patients receiving atorvastatin 80 mg daily.
• Correlated lipoprotein levels with cardiovascular events occurring between randomization and 16 weeks.

Main Results:

• Baseline LDL-C did not predict clinical outcomes.
• Baseline HDL-C was a significant predictor of outcome, with higher levels associated with reduced risk (HR 0.986 per mg/dL increment, P<0.001).
• Atorvastatin significantly reduced LDL-C but had minimal impact on HDL-C. Week 6 LDL-C or its change from baseline did not predict events between weeks 6 and 16.

Conclusions:

• Plasma HDL-C levels at the onset of ACS are predictive of subsequent cardiovascular event risk.
• The risk reduction observed with atorvastatin in ACS is not solely attributable to LDL-C reduction.
• Potential mechanisms for atorvastatin's benefit may involve qualitative LDL particle changes or non-lipid pleiotropic effects.